FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 60 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery MOST POPULAR Wales: 4 in 10 with possible cancer symptoms didn’t contact GP June 17, 2021 Poziotinib Shows Promise in EGFR and HER2 Exon 20 Mutated Non-Small... March 2, 2021 Contact X-ray Brachytherapy Dose Escalation Increases the Organ Preservation Rate in... November 29, 2024 New study identifies how obesity may increase the risk of developing... April 19, 2022 Load more HOT NEWS ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... Hairstylist Creates Custom Wigs & Donates Them To Cancer Patients NHS England change of chief executive – what does it mean...
